PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 8, 2019Cardiovascular Drugs and Therapy63 citationsOpen Access

Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial

GLGavin A. LewisESErik B. SchelbertJNJosephine H. Naish

Key Points

  • To evaluate the efficacy of pirfenidone in treating heart failure with preserved ejection fraction.
  • Randomized trial design
  • Participants with heart failure and preserved ejection fraction
  • Trial registered as NCT02932566
  • Efficacy outcomes related to ejection fraction will be measured
  • Potential benefits of pirfenidone will be assessed in the heart failure population

Abstract

clinicaltrials.gov (NCT02932566) https://clinicaltrials.gov/ct2/show/NCT02932566.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lewis et al. (2019) studied this question.

synapsesocial.com/papers/69d576d1c81cc4d948f44932https://doi.org/10.1007/s10557-019-06876-y
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction2021 · 13 citations
  2. 2Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant2024 · 9 citations
  3. 3A39-20 SURPASS-IPF: Study Design of a Phase 3, Head-to-head Trial of Deupirfenidone Compared to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis2026
  4. 4Impact of Pirfenidone on arrhythmic and clinical outcomes in patients with idiopathic pulmonary fibrosis2024
  5. 5Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction2022 · 7 citations